Kodu・Aktsiate loetelu・Novavax Inc

Novavax Inc

Suletud

SektorTervishoid

7.46 -4.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.45

Max

7.86

Põhinäitajad
By Trading Economics
Sissetulek	-27M -9.5M
Müük	-7.6M 140M
P/E Sektori keskmine	3.112 62.58
Aktsiakasum	-0.06
Kasumimarginaal	-6.803
Töötajad	749
EBITDA	-29M -543K

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+37.47% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-25M 1.3B
Eelmine avamishind	11.82
Eelmine sulgemishind	7.46

Uudiste sentiment

By Acuity

19%

81%

32 / 340 Pingereas Healthcare

Novavax Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23. juuli 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22. juuli 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21. juuli 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20. juuli 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Novavax Inc Prognoos

Hinnasiht

By TipRanks

37.47% tõus

12 kuu keskmine prognoos

Keskmine 10.75 USD 37.47%

Kõrge 19 USD

Madal 7 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Novavax Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Novavax Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

32 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.